Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings | Zendy

Andrew Hill | Zendy; Angela McBride | Zendy; Anthony Sawyer | Zendy; Nathan Clumeck | Zendy; Ravindra K. Gupta | Zendy

Open Access

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings

Author(s) -

Andrew Hill,

Angela McBride,

Anthony Sawyer,

Nathan Clumeck,

Ravindra K. Gupta

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit112

Subject(s) - resistance mutation , confidence interval , medicine , reverse transcriptase inhibitor , antiretroviral therapy , protease inhibitor (pharmacology) , virology , drug resistance , viral load , gastroenterology , human immunodeficiency virus (hiv) , reverse transcriptase , biology , polymerase chain reaction , microbiology and biotechnology , biochemistry , gene

Increases in the prevalence of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been observed among previously untreated individuals in all areas of sub-Saharan Africa. We aimed to examine whether first-line use of 2 NRTIs plus a boosted protease inhibitor (bPI) could protect against emergence of NRTI resistance mutations, compared to the use of 2 NRTIs plus 1 NNRTI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research